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Abstract 
Objectives: Diabetic cardiomyopathy (DCM) is an established complication of diabetes mellitus. 
In West Virginia, the especially high incidence of diabetes and heart failure validate the necessity of 
developing new strategies for earlier detection of DCM. Since most DCM patients remain 
asymptomatic until the later stages of the disease when the fibrotic complications become irre-
versible, we aimed to explore biomarkers that can identify early-stage DCM. Methods: The pa-
tients were grouped into 4 categories based on clinical diabetic and cardiac parameters: Control, 
Diabetes (DM), Diastolic dysfunction (DD), and Diabetes with diastolic dysfunction (DM+DD), the last 
group being the preclinical DCM group. Results: Echocardiography images indicated severe di-
astolic dysfunction in patients with DD+DM and DD compared to DM or control patients. In the 
DM and DM+DD groups, TNFα, isoprostane, and leptin were elevated compared to control 
(p<0.05), as were clinical markers HDL, glucose and hemoglobin A1C. Fibrotic markers IGFBP7 
and TGF-β followed the same trend. The Control group showed higher beneficial levels of adi-
ponectin and bilirubin, which were reduced in the DM and DM+DD groups (p<0.05). Conclusion: 
The results from our study support the clinical application of biomarkers in diagnosing early stage 
DCM, which will enable attenuation of disease progression prior to the onset of irreversible 
complications. 
Key words: cardiomyopathy, diabetes, West Virginia, serum biomarkers. 
Introduction 
In recent years, diabetes mellitus (DM) has be-
come a national health epidemic. The Centers for 
Disease Control and Prevention reports that West 
Virginia has one of the highest rates of diabetes in the 
United States with more than 11% of the population 
affected. The Framingham Heart Study revealed that 
the risk of heart failure is up to 5 times higher in dia-
betics than non-diabetics, when controlling for other 
risk factors. Diabetic Cardiomyopathy (DCM) is an 
established complication of diabetes [1-6] that in-
volves abnormal relaxation of the ventricles, referred 
to as diastolic dysfunction, with concurrent hyper-
trophy of cardiomyocytes [6, 7]. Diastolic dysfunction 
is thought to be the first functional abnormality in 
DCM and can be seen in 40-60% of asymptomatic di-
abetic patients through echocardiographic imagining 
studies [2, 6]. Diabetic patients with subclinical dias-
tolic dysfunction have a 5-year mortality rate of 30.8% 
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compared to 12.1% for diabetic patients with no di-
astolic dysfunction [4]. As DCM enters its later stage, 
it progresses from diastolic dysfunction to overt stage 
C heart failure with preserved ejection fraction, which 
has no proven effective treatment [7], thus validating 
the importance of identifying biomarkers that can 
improve detection of DCM prior to the onset of irre-
versible complications. 
Diabetes impairs glucose uptake and results in 
an increase in fatty acid (FA) metabolism in cardiac 
tissue [3, 8, 9]. In diabetes, decreased insulin signaling 
activates transcriptional signaling pathways that in-
duce the expression of genes involved in stimulating 
FA uptake; however the uptake of FAs exceeds met-
abolic demand and results in triglyceride and choles-
terol accumulation in the myocardium which impairs 
diastolic function [8-11]. A study by McGavock et al 
compared normoglycemic individuals with diabetic 
patients and confirmed a positive correlation between 
impaired glucose tolerance and myocardial triglycer-
ide content and found that triglyceride accumulation 
preceded the onset of ventricular dysfunction [11]. 
Abnormal FA metabolism also leads to depressed 
levels of high-density lipoprotein (HDL) [3].  
Multiple studies have established a link between 
damage induced by oxidative stress and DCM [12, 
13]. Damage from oxidative stress due to the chronic 
mitochondrial overproduction of reactive oxygen 
species (ROS) plays a crucial role in inflammation and 
results in irreversible fibrosis and cardiomyocyte 
death [2, 12, 14, 15]. Inflammation in the myocardium 
is mediated by pro-inflammatory cytokines including 
TNFα and interleukin-6 [16]. Isoprostanes are formed 
by the peroxidation of polyunsaturated FAs and are 
considered an accurate reflection of the extent of oxi-
dative damage [17]. Amelioration of oxidative stress 
on a molecular level can be achieved through induc-
tion of antioxidant agents, and studies have shown 
that enhancing mitochondrial ROS scavenging sys-
tems mitigates diabetes-induced cardiac dysfunction 
[2, 12, 18-21]. Bilirubin, a product of heme catabolism, 
is a potent antioxidant and under normal physiologi-
cal conditions may attenuate many ROS-derived 
complications of DCM [22, 23]. Adiponectin is a 
hormone secreted by adipose tissue that regulates 
metabolic processes and functions as an antioxidant; 
the low plasma levels of adiponectin seen in diabetes 
contribute to the oxidative damage seen in DCM [24, 
25].  
 Structurally, the progression of DCM has been 
linked to cardiomyocyte hypertrophy and increased 
fibrosis [26-29]. The presence of cardiomyocyte hy-
pertrophy was supported by data from The Fram-
ingham Heart Study, which revealed left ventricular 
mass was higher in diabetics compared to 
non-diabetics independent of covariates [30]. Hyper-
glycemia facilitates the reaction of glucose with col-
lagen to form advanced glycation end-products (AG-
Es) that promote the crosslinking of collagen mole-
cules to produce fibrosis [26]. Insulin-like growth 
factor binding protein 7 (IGFBP7) is a modulator of 
insulin-like growth factors, which actively regulate 
insulin consumption and receptor activity [27]. 
IGFBP7 has been identified as a biomarker for dias-
tolic dysfunction associated with cardiac hypertro-
phy, myocyte fibrosis, and vascular remodeling, and 
an association exists between serum IGFBP7 levels 
and echocardiographic abnormalities describing di-
astolic heart dysfunction independent of systolic 
function [28]. In diabetics, increased ROS production 
causes the subsequent release of the profibrotic 
marker transforming growth factor beta (TGF-β) [29]. 
TGF-β levels correlate with the degree of cardiac fi-
brosis [26]. The reliable early detection of fibrotic 
changes in DCM patients by IGFBP7 and TGF-β is 
clinically pertinent since current experimental thera-
pies designed to prevent progression of DCM include 
targeting collagen deposition and fibrosis through 
AGE inhibitors and AGE cross-link breakers [1, 6]. 
The aim of this study was to investigate a panel 
of biomarkers, including fibrotic markers, antioxi-
dants, markers of oxidative stress and a metabolic 
profile that can be used to detect DCM prior to the 
presentation of clinical signs. Early stage DCM is ini-
tially asymptomatic and reversible; however, DCM is 
a progressive disease and at the later stage prognosis 
becomes poor. Analysis of biomarkers would be a 
simple, noninvasive diagnostic tool with a high pre-
dictive value for clinical use in patients with the po-
tential to develop DCM, which would allow for the 
implementation of therapeutic strategies to be started 
in time to delay and mitigate the disease progression. 
Materials and Methods 
Patients 
This study comprised of 100 patients, divided 
into 4 categories based on predetermined clinical di-
abetic and cardiac parameters: 1. Control; 2. Diabetes 
with normal diastolic function; 3. Diastolic dysfunc-
tion without diabetes; 4. Diabetes and diastolic dys-
function. Contraindications to inclusion included any 
systolic dysfunction observed through echocardiog-
raphy, evidence of prior myocardial infarction, 
known valvular or congenital heart disease or other 
significant comorbidities, including malignancy, renal 
failure, or significant psychiatric illness. The study 
was approved by the Ethics Committee of Cabell 
Huntington Hospital, West Virginia. All of the sub-
jects signed a written informed consent form.  
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Table 1: Demographic Profile 
Groups Control  
 
Diastolic 
dysfunction 
(DD) 
 
Diabetes 
mellitus 
(DM) 
Diabetes mellitus with 
diastolic dysfunction 
(DM+DD) 
Age (yrs.) 41.67±11.79 44.27±8.31 48±11.78 45.69±8.42 
Sex (M/F) 43%/57% 50%/50% 52%/48% 57%/43% 
 
 
Blood Samples 
Venous blood was drawn from an antecubital 
vein in heparinized and Vacutainer tubes for serum 
levels of TNFα, IL-6, Isoprostane, leptin, adiponectin, 
bilirubin, IGFBP7, TGF-β and lipid and glucose pro-
files. Blood was processed after collection and serum 
collected for analysis. Serum was collected by spin-
ning down the vacutainer tube at 2000 rpm for 5 
minutes at 4°C and stored at -80°C until analysis.  
Analysis of Biomarkers 
Serum samples frozen at -80°C were analyzed 
for levels of the following biomarkers through en-
zyme-linked immunosorbent-assay (ELISA): TNFα, 
IL-6, adiponectin and leptin (EMD Millipore, Temec-
ula, Ca), Isoprostane (Cayman Chemical Company, 
Ann Arbor, MI), bilirubin (Sigma-Aldrich, St. Louis, 
MO), triglycerides (Abcam, Cambridge, MA), and 
IGFBP7 and TGF-β (kits from R&D Systems, Minne-
apolis, MN). ELISAs were conducted in accordance to 
the manufacturer’s protocol.  
Echocardiography 
Patients underwent echocardiography with 2D, 
Doppler, and color flow imaging within the year prior 
to enrollment. Studies were performed on a Philips IE 
33 with an S5 transducer by one of 2 certified echo 
technicians in an ICAEL- accredited laboratory. 
Measurements were obtained in accordance with 
guidelines set forth by the American Society of Echo-
cardiography [31] 2D imaging was used to assess 
ejection fraction (EF), septal wall thickness, posterior 
wall thickness and left atrial size. Relative wall thick-
ness was calculated with posterior and septal wall 
thickness by (2×PWTd)/LVIDd [32]. Mitral valve in-
flow Doppler was recorded, including E and A waves. 
Tissue Doppler was used for E’ and A’. Echocardio-
graphic images were read by physicians who were 
blinded to the rest of the study. 
Statistical Analysis 
 Data were analyzed using Graphpad Prism 4.0. 
Equal variance was assured by Bartlett’s test for each 
biomarker within each of the four patient categories. 
ANOVA was conducted to identify statistically sig-
nificant differences in the mean serum levels for the 
different biomarkers. The Tukey post-hoc test was 
used to indicate which patient groups showed statis-
tically significant differences for the biomarker level 
measured.  
Results 
Echocardiography 
All patients underwent transthoracic echocar-
diography to evaluate left ventricular diastolic filling 
pressure. Patients were identified as normal or as 
having diastolic dysfunction (DD), with DD encom-
passing a spectrum of severities including impaired 
relaxation, pseudonormal and restrictive diastolic 
dysfunction (Fig. 1). Results from echocardiographic 
imaging studies were used in conjunction with the 
diabetic status of the patients to establish the 4 patient 
categories. 
TNFα, isoprostane and IL-6 levels 
TNFα, isoprostanes, and IL-6 are inflammatory 
mediators that correlate with the extent of oxidative 
damage in tissues. TNFα and IL-6 were found to be 
elevated in DM, DD and DM+DD patients when 
compared to the control group (Fig. 2A and B respec-
tively; p < 0.05). Levels of TNFα and IL-6 were signif-
icantly higher in patients with DM+DD than the levels 
found in either the patients with DM or the patients 
with DD alone (p < 0.05). Patients with DM and pa-
tients with DM+DD had increased levels of isopros-
tane compared to the control (Fig. 2C). Additionally, 
isoprostane levels in patients with DM+DD were 
higher than levels observed in patients with DD alone 
(p < 0.05). 
Table 2: Patient Clinical Profile. 
 BMI Triglycerides (mg/dL) HDL (mg/dL) Glucose (mg/dL) HbA1C (mg/dL) 
Control 23.89 (±1.01) 61.12 (±11.02) 67.60 (±3.96) 91.50 (±4.50) 5.20 (±0.11) 
DM 39.79* (±1.82)  85.72 (±8.62) 43.60* (±2.04)  186.28* (±3.97)  8.04* (±0.12)  
DD 31.42# (±2.70) 92.16 (±8.10)  44.42* (±3.85)  107.23# (±24.14)  5.72# (±0.50)  
DM+DD 39.44* (±2.68)  113.05* (±9.39) 39.50* (±1.97)  172.9* (±13.66)  7.36*+ (±0.29)  
Values represent means ± SEM. * p<0.05 vs Control; # p<0.05 vs DM; + p<0.05 vs DD. 
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Figure 1: Mitral inflow velocities representing normal physiology as well as the spectrum of diastolic dysfunction. A: Normal. B: Impaired Relaxation. C: 
Grade II diastolic dysfunction (pseudonormalization). D: Restrictive 
 
 
Figure 2: Assay of serum concentrations of (A) TNFα, (B) IL-6 and (C) Isoprostane in Control, DM, DD and DM+DD patient groups. Values represent 
means ± SEM. * p<0.05 vs CTR; # p<0.05 vs DM, + p<0.05 vs DD. 
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Leptin, adiponectin and bilirubin levels 
Leptin is an adipose-derived hormone that 
stimulates energy expenditure and is proportional to 
the amount of body fat. Leptin was significantly 
higher in the DM, DD and DM+DD patients when 
compared to the control group and was also signifi-
cantly increased in the DM+DD patients when com-
pared to the patients with DD alone (Fig. 3A; p < 0.05). 
Adiponectin was significantly lower in DM, DD, and 
DM+DD patients when compared to control groups 
(Fig.3B). Adiponectin was also significantly decreased 
in DM+DD patients when compared to patients with 
DM and DD alone (p < 0.05). Bilirubin, a potent anti-
oxidant, was found to be lowered in the DM+DD 
group compared to the control (Fig. 3C; p < 0.05). 
TGF-β and IGFBP7 levels 
TGF-β correlates to the extent of fibrosis and 
IGFBP7 has been linked to cardiomyocyte hypertro-
phy and fibrosis. In concordance with our hypothesis, 
TGF-β levels were elevated in DM, DD and DM+DD 
patients when compared to the control group (Fig. 4A; 
p < 0.05). DM+DD patients did have significantly 
higher TGF-β levels than the DM group alone. IGFBP7 
was found to be increased in the DM, DD and 
DM+DD groups compared to the control. IGFBP7 was 
also higher in patients with DM+DD compared to 
patients with DM or DD alone (Fig. 4B; p < 0.05). 
 
 
Figure 3: Serum levels of (A) Leptin, (B) Adiponectin and (C) Bilirubin in Control, DM, DD and DM+DD patient groups determined by ELISA. Values 
represent means ± SEM. * p<0.05 vs CTR; # p<0.05 vs DM, + p<0.05 vs DD. 
 
 
Figure 4: Assay of serum concentrations of (A) TGF-β and (B) IGFBP7 in Control, DM, DD and DM+DD patient groups. Values represent means ± SEM. 
* p<0.05 vs CTR; # p<0.05 vs DM, + p<0.05 vs DD. 
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Discussion  
This study demonstrated that a panel of bi-
omarkers in conjunction with echocardiography plays 
an important role in the detection of DCM prior to the 
manifestation of symptoms and irreversible compli-
cations. Our data indicated that early stage DCM can 
be characterized by elevated levels of inflammatory 
markers, decreased antioxidant markers and, most 
importantly, increased levels of the fibrotic markers 
IGFBP7 and TGF-β. These results, which are summa-
rized in the schematic diagram (Fig. 5), identified po-
tential biomarkers that can be used clinically to im-
prove early diagnosis of DCM.  
 The clinical parameters studied include BMI and 
levels of triglycerides, HDL, glucose and HbA1C. A 
comprehensive national study, which substantiates 
the correlation between BMI and diabetes, found that 
individuals with diabetes were more likely to have a 
high BMI [33]. In concordance with established stud-
ies, our results demonstrated elevated blood glucose 
levels and HbA1C levels in both DM patients and 
patients with DM+DD. As expected, neither glucose 
nor HbA1C was elevated in DD patients, because DD 
is not specific to DCM but can result from hyperten-
sion, aortic stenosis, myocardial infarction, or systolic 
heart failure [31]. Triglycerides are elevated in dia-
betic patients due to an increased reliance on fatty 
acid metabolism, and our data demonstrated DM+DD 
patients had significantly elevated triglyceride levels. 
Additionally, our data supported the accepted trend 
that diabetes is closely associated with reduced levels 
of HDL. 
  Elevated levels of the inflammatory cytokines 
TNFα and IL-6 are associated with diabetes, and pre-
vious studies have indicated their role in cardiac re-
modeling, fibrosis and cardiomyocyte apoptosis [34]. 
In corroboration with these findings, our study 
demonstrated elevated levels of TNFα and IL-6 rela-
tive to the control in DM, DD, and DM+DD patients, 
with the highest levels in DM+DD patients, support-
ing their utilization in the early detection of DCM and 
amelioration of disease progression. Isoprostane, an 
established marker of oxidative stress [11], was in-
creased in patients with DM+DD. Our results also 
demonstrate a decreased level of the antioxidant bil-
irubin in patients with DM+DD, which supports pre-
vious findings that bilirubin is negatively associated 
with diabetes and its complications. 
Leptin is closely associated with obesity and its 
comorbidities [35], and was highest in patients with 
DM and patients with DM+DD, which were the 
groups with the highest BMIs. There is an inverse 
relationship between adiponectin and leptin levels, 
with low adiponectin levels indicating metabolic and 
cardiovascular disease [36]. Adiponectin has antidia-
betic effects and antagonizes the progression of DCM 
by exhibiting potent anti-hypertrophic activity in 
cardiomyocytes and diminishing cardiac cell death by 
inhibiting inflammation [36-38]. Consistent with pre-
vious studies, our data identified decreased levels of 
adiponectin in DM patients and DD patients and sig-
nificantly lower adiponectin levels in DM+DD pa-
tients, which indicated a diminished ability to offset 
the DCM complications and progression.  
IGFBP7 is an established marker for diabetes, 
and is associated with the severity of diastolic 
dysfunction [28]. IGFBP7 also has been impli-
cated in fibrogenesis in diabetic patients, and 
increasing concentrations correlate with in-
creased collagen deposition, which, in cardiac 
tissue, may contribute to diastolic stiffness 
[39]. Diabetes-induced ROS generation 
up-regulates the expression of the profibrotic 
marker TGF-β, leading to increased extracel-
lular matrix synthesis and fibrosis [26]. In-
creased collagen deposition and interstitial 
fibrosis are key pathogenic components of 
DCM that result in myocardial stiffness, which 
manifests as diastolic dysfunction [2]. In con-
cordance with previous studies, our data in-
dicated elevated IGFBP7 and TGF-β levels in 
DM, DD and DM+DD patients, with DM+DD 
patients displaying the highest values. There-
fore, these markers play an important role in 
the early detection of DCM and cardiac fibro-
sis, enabling early intervention to attenuate 
disease progression. 
 
Figure 5: Schematic depicting the progression from diabetes to DCM and the role of 
biomarkers to detect early stage DCM and attenuate disease progression. 
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Conclusion 
In conclusion, our study identified a panel of 
biomarkers that can complement echocardiographic 
imaging studies to detect the diabetes-induced 
changes in cardiac structure and function present at 
the early stage of DCM. The progression of DCM from 
subclinical diastolic dysfunction to overt heart failure, 
and the associated high morbidity and mortality in 
the later stage of the disease, validates the need for 
reliable early diagnostic tools. The results of our clin-
ical study can improve early diagnosis of DCM and 
help successfully implement preventative strategies 
that may slow or prevent development of the disease.  
 Our study advances the understanding of the 
clinical use of biomarkers in the diagnosis of DCM in 
a rural Appalachian population. Diabetes is a chronic 
disease with high prevalence in West Virginia, and its 
comorbidities present a significant public health con-
cern. Therefore, West Virginia patients present the 
ideal population to study strategies for earlier detec-
tion of DCM. Positive results from this study will 
benefit this underserved population by enabling an 
earlier and more reliable diagnosis of DCM so that 
therapy can be administered in time to attenuate dis-
ease progression. 
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